Sphere-9 Catheter Ablation for Atrial Fibrillation

(Conquer-AF Trial)

This trial tests a redo procedure for individuals with atrial fibrillation (AF), a condition characterized by an irregular heartbeat. The Sphere-9 Catheter and Affera Ablation System aim to improve AF symptom management after a previous ablation was insufficient. Participants must have experienced a return of AF symptoms following a single prior ablation procedure. The study will monitor participants for a year to evaluate the treatment's effectiveness. As an unphased trial, it provides participants the chance to contribute to the advancement of AF treatment options.

The trial does not specify if you need to stop taking your current medications. However, you must be on oral anticoagulation therapy for at least 3 weeks before the ablation procedure.

Research has shown that the Sphere-9 Catheter, used to remove tissue in atrial fibrillation (AF), is generally safe. Studies found that only 1.4% of patients experienced significant issues, indicating that problems were rare. Another study reported an even lower rate of 0.6%, with no serious complications such as harmful connections between the esophagus and heart or sudden narrowing of heart blood vessels.

The Sphere-9 Catheter Ablation is unique because it combines both mapping and ablation functions in a single device, which could streamline the procedure for atrial fibrillation (AF). Traditional treatments like radiofrequency or cryoablation require separate catheters for mapping and ablation, making the process more complex and time-consuming. Researchers are excited because the Sphere-9 Catheter may improve precision and efficiency, potentially leading to better patient outcomes and reduced procedure times. This integrated approach could represent a significant advancement in the treatment of AF, offering a more effective and patient-friendly option.

Research has shown that the Sphere-9 Catheter Ablation effectively treats atrial fibrillation (AF), a type of irregular heartbeat. One study reported that 74% of patients did not experience a significant return of AF within a year after the procedure. Another study found that 78.3% of patients with occasional AF and 77.9% with ongoing AF remained free from irregular heartbeats after one year. Specifically, 155 patients treated with this system did not experience irregular heartbeats again within 12 months. The Sphere-9 Catheter Ablation combines different energy types to target abnormal heart tissue, proving safe and effective for treating ongoing AF.¹³⁶⁷⁸